A new market assessment report on prenatal testing and newborn screening market brings to light a detailed statistics on the dramatic shift in the competitive landscape and business environment of the prenatal testing and newborn screening market for the forecast period 2020 - 2027. The comprehensive study offers an overview of the current state of development of the business as well as predicts the course of progress across different regions. A large number of factors including the major driving forces, threats and opportunities are taken into account to present an analytical picture of the industry portrayed in the report.

The global prenatal testing and newborn screening market is projected to be worth USD 10.85 Billion by 2027, according to a current analysis by Emergen Research. The prenatal testing and newborn screening market is observing high demand attributed to its increasing application in detecting fetal chromosome defects. Prenatal testing is considered superior to other screening modalities, particularly for trisomy 21 (one of the most prevalent congenital anomalies). Prenatal testing enables individuals to make informed decisions as to whether diagnostic testing should be carried out. Associated fetal chromosomal anomalies typically include the benefit or lack of genetic material that can differ from small segments to small segments of chromosomes to entire chromosomes.

Read more@ https://www.emergenresearch.com/industry-report/prenatal-testing-an...

Key Highlights From The Report

In April 2019, Progenity Inc. made an announcement about the introduction of the Resura Prenatal Test, a non-invasive, personalized prenatal check for monogenetic diseases.

Ultrasonography is projected to observe a significant growth rate in the forecast period, owing to the ability of the ultrasound diagnosis to detect anomalies in the position of the baby and actions within the womb.

The hospital held a substantial market share in 2019 due to the growing introduction of non-invasive prenatal testing, coupled with rapid technological developments in newborn screening, the presence of skilled professionals, and better reimbursement scenario.

North America dominated the market for Prenatal Testing and Newborn Screening in 2019 due to the availability of technologically advanced healthcare research system and developments in whole-genome sequencing.

Key participants include Abbott Laboratories, Bio-Rad Laboratories, Color Genomics, Edinburgh Genomics, Eurofins Scientific, Agilent Technologies, CRISPR, Illumina Inc., Editas Medicine, and Qiagen NV, among others.

Request For Free Sample@ https://www.emergenresearch.com/request-sample/346